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OBJECTIVE—Genome-wide association scans (GWASs) have
identiﬁed novel diabetes-associated genes. We evaluated how
these variants impact diabetes incidence, quantitative glycemic
traits, and response to preventive interventions in 3,548 subjects
at high risk of type 2 diabetes enrolled in the Diabetes Prevention
Program (DPP), which examined the effects of lifestyle interven-
tion, metformin, and troglitazone versus placebo.
RESEARCH DESIGN AND METHODS—We genotyped se-
lected single nucleotide polymorphisms (SNPs) in or near diabe-
tes-associated loci, including EXT2, CDKAL1, CDKN2A/B,
IGF2BP2, HHEX, LOC387761, and SLC30A8 in DPP participants
and performed Cox regression analyses using genotype, interven-
tion, and their interactions as predictors of diabetes incidence.
We evaluated their effect on insulin resistance and secretion at 1
year.
RESULTS—None of the selected SNPs were associated with
increased diabetes incidence in this population. After adjust-
ments for ethnicity, baseline insulin secretion was lower in
subjects with the risk genotype at HHEX rs1111875 (P  0.01);
there were no signiﬁcant differences in baseline insulin sensitiv-
ity. Both at baseline and at 1 year, subjects with the risk genotype at
LOC387761 had paradoxically increased insulin secretion; adjust-
ment for self-reported ethnicity abolished these differences. In
ethnicity-adjusted analyses, we noted a nominal differential im-
provement in -cell function for carriers of the protective genotype
at CDKN2A/B after 1 year of troglitazone treatment (P  0.01) and
possibly lifestyle modiﬁcation (P  0.05).
CONCLUSIONS—We were unable to replicate the GWAS ﬁnd-
ings regarding diabetes risk in the DPP. We did observe genotype
associations with differences in baseline insulin secretion at the
HHEX locus and a possible pharmacogenetic interaction at
CDKNA2/B. Diabetes 57:2503–2510, 2008
T
he increasing incidence of diabetes continues to
have a tremendous impact on diabetes-related
morbidity and mortality around the world. Al-
though much emphasis has been placed on the
contribution of a Western lifestyle characterized by in-
creasing caloric intake and physical inactivity to the
diabetes epidemic, the role genetics plays in the develop-
ment of diabetes is generally poorly understood. Addi-
tional insight into the contribution of genetic variants to
diabetes incidence, gene-lifestyle interactions, and phar-
macological response to antidiabetes medications is re-
quired to slow this tragic epidemic.
The recent implementation of genome-wide association
scans (GWASs) as an investigative tool has resulted in a
qualitative leap in identifying diabetes-related genes (1,2).
These surveys, which are agnostic to candidate genes, can
cover 80% of common human genome variants with
current technology, thus providing unprecedented insight
into the genetic architecture of type 2 diabetes. In 2007,
the ﬁrst published type 2 diabetes GWAS conﬁrmed the
important impact of TCF7L2 on diabetes incidence (odds
ratio [OR] 1.65, P  1.0  10
7) and identiﬁed several new
type 2 diabetes loci, SLC30A8 (1.26, P  5.0  10
7),
HHEX (1.21, P  9.1  10
6), LOC38771 (1.14, P  2.9 
10
4), and EXT (1.26, P  1.2  10
4) (3). SLC30A8
encodes a zinc transporter protein that carries zinc from
the cytoplasm into insulin secretory vesicles within the
pancreatic -cell, an important step in insulin synthesis
and secretion (4). HHEX is essential for the development
of the pancreas and liver and is a target of the Wnt
signaling pathway (5).
After the initial GWAS publication, four other high-
density scans were published simultaneously by different
groups, conﬁrming many of the initial ﬁndings. In addition
to replicating the prior associations of TCF7L2, HHEX,
and SCL30A8, investigators from Iceland identiﬁed CDK5
regulatory subunit associated protein 1-like 1 (CDKAL1)
as another potential diabetes-related gene (OR 1.2, P 
1.8  10
4) (6). This gene is hypothesized to lead to -cell
degeneration by modulating CDK5/CDK5R1 activity. The
Diabetes Genetics Initiative, the Wellcome Trust Case
Control Consortium, and the Finland–U.S. Investigation of
Type 2 Diabetes Genetics concomitantly published GWASs
that were combined in a preliminary meta-analysis of
30,000 samples (7–9). Again, the above ﬁndings were
conﬁrmed, and novel diabetes loci in or near IGF2BP2
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16) and CDKN2A/B (1.2, P  7.8 
10
15) were identiﬁed. The EXT2 and LOC387761 gene
regions have not been replicated in these or additional
studies (10,11). Taken together, these studies support the
potential power of GWASs in unraveling the genetic basis
of type 2 diabetes.
Several studies have attempted to characterize the phys-
iological mechanisms affected by these genetic variants.
Pascoe et al. (12) performed 75-g oral glucose tolerance
tests (OGTTs) and hyperinsulinemic-euglycemic clamps
on 1,276 healthy European subjects and demonstrated that
common variants in CDKAL1 and HHEX are associated
with decreased pancreatic -cell function. Grarup et al.
(13) reported that variants of HHEX, CDKN2A/B, and
IFG2BP2 are associated with type 2 diabetes, and single
nucleotide polymorphisms (SNPs) within the HHEX and
CDKN2A/B loci impaired glucose-induced insulin release
in healthy subjects, emphasizing the central role of pan-
creatic -cell dysfunction in disease pathogenesis. Staiger
et al. (14) found that the major alleles of the SLC30A8 and
the HHEX SNPs associate with reduced insulin secretion
stimulated by orally administered glucose but not with
insulin resistance; the other reported type 2 diabetes SNPs
within the EXT2 and LOC387761 loci did not associate
with insulin resistance or -cell dysfunction. Finally, a
quantitative trait analysis of GWAS-identiﬁed type 2 diabe-
tes susceptibility loci was recently completed by Palmer et
al. (15) in their analysis of the Insulin Resistance Athero-
sclerosis Family Study (IRAS-FS). This study of 1,268
Hispanic and 581 African American subjects revealed that
the increase in diabetes risk associated with variants in
GWAS-identiﬁed gene regions, including CDKAL1,
IGF2BP2, SLC30A8, and LOC387761, is mediated in part
via defects primarily in insulin secretion. In Hispanic
Americans, the acute insulinogenic response to glucose
challenge decreased in high-risk genotype subjects at
CDKAL1 (P  0.005), and the disposition index was
reduced in subjects with the high-risk genotype at
IGF2BP2 (P  0.01). Paradoxically, in Hispanic Ameri-
cans, the previously identiﬁed risk allele of LOC387761
was signiﬁcantly associated with an increased acute insu-
lin response (P  0.005) and disposition index (P  0.036).
IGF2BP2 rs4402960 was the only GWAS-identiﬁed SNP
that associated with type 2 diabetes as a categorical trait
(P  0.02). Even fewer studies have attempted to analyze
the inﬂuence of these genetic variants on response to
pharmacological or behavioral interventions (16,17).
The current study attempts to replicate and extend
recent GWAS ﬁndings in the Diabetes Prevention Program
(DPP) cohort. As a multiethnic, interventional study of
3,000 people at high risk for diabetes who have been
carefully characterized, the DPP provides the opportunity
to study insulin dynamics according to genotype and
potential drug-genotype interactions. Studying pre-dia-
betic subjects as opposed to patients with overt diabetes
provides insight into the role of genetic variation in the
early stages of disease progression. As a longitudinal
interventional study, the DPP provides the opportunity to
carefully study the impact of genetic variation on insulin
secretion and resistance over time. Finally, having multi-
ple treatment arms allows for the identiﬁcation of poten-
tial interactions of genotype with the results of the
interventions. Studying gene-treatment interactions helps
elucidate mechanisms of disease, identify speciﬁc treat-
ments that may ameliorate the genetic predisposition to
disease, and focus on subgroups that respond particularly
well (or poorly) to speciﬁc therapies.
RESEARCH DESIGN AND METHODS
DPP. Details of the DPP study design have been described elsewhere (18).
The DPP is a multicenter trial that examined whether lifestyle modiﬁcation or
metformin therapy prevents the development of diabetes in individuals with
risk factors for type 2 diabetes, including elevated fasting glucose, impaired
glucose tolerance, overweight or obesity, and sedentary lifestyle. The DPP
randomly assigned 3,819 subjects at high risk of diabetes to lifestyle modiﬁ-
cation (7% weight loss and 150 min of physical exercise weekly), met-
formin (850 mg twice daily), troglitazone (400 mg daily), or placebo. The
troglitazone arm with 585 participants was stopped early because of medica-
tion-related hepatotoxicity. The primary end point was the development of
diabetes conﬁrmed by two consecutive measures of glucose. The trial was
conducted at 27 centers, all of which obtained institutional review board
approval. The distribution of self-reported ethnicities among the 3,548 partic-
ipants in this genetic study was 56.4% Caucasian, 20.2% African American,
16.8% Hispanic, 4.3% Asian, and 2.4% American Indian. The mean age was 51
years, and the mean BMI was 34.0 kg/m
2. There was a range of BMI values for
each ethnic group, with Asian/Paciﬁc Islanders having the lowest (29.5 kg/m
2)
followed by Hispanics (33.1 kg/m
2), Caucasians (34.1 kg/m
2), African Ameri-
cans 35.3 (kg/m
2), and American Indians (35.4 kg/m
2). After an average of 3
years of follow-up, the lifestyle modiﬁcation group had a 58% reduction in
diabetes incidence, whereas the metformin group had a 31% reduction
compared with placebo (19).
SNP selection and genotyping. We selected SNPs that had been highly
associated with type 2 diabetes at high levels of statistical signiﬁcance in
previous high-density (300,000–500,000) GWAS analyses (3,7–9). DNA was
extracted from peripheral blood leukocytes with standard methods. Genotyp-
ing was carried out by allele-speciﬁc primer extension of multiplex ampliﬁed
products and detection using matrix-assisted laser desorption ionization
time-of-ﬂight mass spectrometry on a Sequenom iPLEX platform (20,21). The
mean genotyping success rate was 99.5%. The minimum call rate was 98.8%.
All SNPs were in Hardy-Weinberg equilibrium (HWE) within each self-
reported ethnic group. We genotyped one SNP per gene for all genes with the
exception of HHEX and EXT2 for which multiple SNPs were tested. In HHEX,
the SNPs rs79238327 and rs1111875 are in linkage disequilibrium in the
HapMap CEU population (r
2 0.69, D 0.959) but not the YRI population
(rs79238327 is monomorphic for the G allele in YRI). The three EXT2 SNPs are
in linkage disequilibrium for both the YRI and CEU populations in the HapMap
Project: all three SNPs are in perfect linkage disequilibrium (r
2 1.0, D 1.0) in
the CEU population, whereas linkage disequilibrium is less strong in the YRI
population (SNPs rs11037909 and rs1113132 [r
2 0.323, D 0.866]; rs11037909
and rs3740878 [r
2 0.43, D 1.0]; and rs1113132 and rs3740878 [r
2 0.881, D 1.0]).
Quantitative glycemic measures. Baseline and annual OGTTs were per-
formed on all subjects who had not developed diabetes before the 1-year
examination and used to calculate the insulin sensitivity index (ISI) and
insulinogenic index. The ISI, the reciprocal of insulin resistance by homeosta-
sis model assessment was calculated as 22.5/[fasting insulin  (fasting
glucose/18.01)] (22). The insulinogenic index was deﬁned as [(insulin at 30
min)  (insulin at 0 min)]/[(glucose at 30 min)  (glucose at 0 min)] (23).
Quantitative traits were measured at baseline and 1 year. We elected to
analyze quantitative traits at 1 year for two reasons: ﬁrst, the greatest effect on
weight loss was observed in the lifestyle modiﬁcation group at year 1, and
second, a substantial number of subjects did not complete the OGTT on the
3rd year (because they had either developed diabetes already or because the
trial ended before they reached that time point) (19).
Statistical analysis. The primary end point of this study was the time to
development of diabetes. We examined genotype (under an additive model),
intervention, and genotype-by-intervention interactions as independent pre-
dictors of time to onset of diabetes using Cox regression models. We also
developed an aggregate risk genotype score for each subject. For each of the
10 SNPs studied, if the genotype was homozygous for the high-risk allele, we
assigned one point; if heterozygous, one-half point; and if homozygous for the
low-risk allele, zero points. We divided the score into quartiles and ran a Cox
regression testing for the relationship between the score category and the
incidence of diabetes. Baseline glycemic variables, the insulinogenic index,
and the ISI were log transformed for non-normality, and the geometric means
were compared across genotypic groups (high-risk homozygotes, heterozy-
gotes, and low-risk homozygotes) by ANOVA (F test). We compared the
glycemic variables at 1 year using ANCOVA models with the independent
variables of genotype and treatment group adjusted for the baseline glycemic
variable with interaction terms of genotype and treatment. All analyses were
repeated after adjusting for sex, age, self-reported ethnicity, and BMI. P values
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using the Holm procedure (24).
We calculated power for predicting diabetes incidence using the methods
of Hsieh and Lavori (25). We assumed HWE within each ethnic group and an
additive genetic model. Assuming there are no gene-treatment interactions,
these calculations show that the overall DPP cohort has 83% power to detect
the previously reported effect size of 1.2 for a SNP of 10% frequency,
whereas the placebo, lifestyle modiﬁcation, and metformin arms have 53, 34,
and 44% power, respectively. The DPP has inadequate power for detecting an
effect size of 1.1 (Supplementary Table 1, available in an online appendix at
http://dx.doi.org/10.2337/db08-0284).
Three hypotheses are tested in the current project. We hypothesized the
following: 1) variants in the genes identiﬁed by the recently completed GWAS
will be associated with the development of type 2 diabetes incidence
prospectively; 2) quantitative traits measuring insulin secretion (insulinogenic
index) and insulin sensitivity (ISI) will vary by genotype at the same
diabetes-associated loci; and 3) genetic variation in these regions will affect
response to metformin, troglitazone, or the lifestyle intervention as reﬂected
in either diabetes incidence or related quantitative traits. To a large extent, the
ﬁrst two hypotheses represent conﬁrmation of previous robust ﬁndings;
therefore, an overall P value of 0.05 was considered statistically signiﬁcant. On
the other hand, the interaction with behavioral and pharmacological interven-
tions represents a novel exploration, and therefore, the nominal P values
should be interpreted after taking into account the number of independent
variants and the three DPP interventions examined.
RESULTS
Diabetes incidence. Risk allele frequencies by ethnicity
are listed in Table 1. The risk allele frequencies were
higher in African American participants compared with
those of European ancestry, with the greatest disparity in
allele frequency between ethnicities at LOC387761 and
IGF2BP2. Risk allele frequencies by ethnicity were com-
pared with the Hap Map European cohort (CEU), HapMap
Yoruba cohort (YRI), and the cohorts studied in the
original GWAS (3,7). Generally, the risk alleles appeared to
be enriched among the DPP white participants compared
with the reference populations (HapMap CEU or the
GWAS original cohorts) and among the DPP African
American participants compared with their white counter-
parts. We did not observe a signiﬁcant association of any
of the reported variants with diabetes incidence in either
the overall cohort or the placebo group (Supplementary
Table 2). Adjustments for self-reported ethnicity or BMI
did not alter the results (Table 2 and Supplementary Table
3). For CDKN2A/B rs10811661, we noted a nominally
signiﬁcant interaction between genotype and intervention;
thus, we stratiﬁed diabetes incidence analyses by treat-
ment arm. For this SNP, a nonsigniﬁcant effect on diabetes
incidence in the placebo arm (hazard ratio 1.21, P  0.13)
was attenuated in the metformin and lifestyle intervention
arms (Table 2). Analysis of the aggregate risk genotype
score identiﬁed a nominally signiﬁcant increase in the
incidence of diabetes for those with a risk allele score of
7.5–9 compared with those with a score of 3.5 (P  0.04).
Baseline quantitative traits. In the crude analyses, we
noted apparent associations of genotype at EXT2
rs3740878 and LOC387761 rs7480010 with baseline -cell
function, as measured by the insulinogenic index (Supple-
mentary Table 4). The EXT2 rs3740878 risk T allele was
nominally associated with reduced insulin secretion in
carriers of the high-risk genotype compared with those
with the low-risk genotype (P  0.01); this difference may
have been driven in part by a compensatory response to
the borderline higher insulin resistance of CC homozy-
gotes. The insulin response at LOC387761 rs7480010 was
paradoxical: The high-risk G allele was associated with
higher insulin secretion (P  0.001), whereas insulin
resistance remained relatively constant in all genotypic
groups. When adjusted for self-reported ethnicity, how-
ever, the above associations at both LOC387761 and EXT2
were abolished. Following such adjustments, the HHEX
rs1111875 high-risk genotype was associated with de-
creased insulin secretion (P  0.01) (Table 3); however,
this association was lost after adjustment for BMI (P 
0.13). The other SNPs tested did not demonstrate any
other signiﬁcant differences in baseline -cell function in
either crude or adjusted analyses (Table 3 and Supplemen-
tary Table 4).
Both HHEX SNPs, rs79238327 and rs1111875, were
nominally associated with decreased insulin sensitivity in
carriers of the risk genotype in crude analyses (P  0.05
and 0.03, respectively). Again, these associations disap-
peared when adjusted for self-reported ethnicity. None of
the other SNPs tested predicted differences in insulin
sensitivity by genotype in either crude or adjusted analy-
ses (Table 3 and Supplementary Table 4).
Follow-up quantitative traits. Before adjustment for
ethnicity, an unexpected higher level of insulin secretion
in carriers of the risk genotype at LOC387761 rs7480010
was again noted in all treatment arms at 1 year, with
nominal statistical signiﬁcance in the combined group
(P  0.001) and placebo arm (P  0.01). Similarly, a
paradoxical trend toward higher insulin secretion in par-
ticipants with the IGF2BP2 rs1470579 high-risk genotype
when compared with the low-risk genotype at baseline
TABLE 1
Risk allele frequencies
Risk allele frequency Reference groups
Marker
SNP
Gene
region Alleles* Caucasian
African
American Hispanic
Asian/Paciﬁc
Islander
American
Indian
HapMap
CEU
HapMap
YRI
GWAS white
cohorts
n 2,001 716 595 151 85
rs1111875 HHEX C/T 60.3 76.7 65.3 37.8 47.6 55.8 85.8 59.8†
rs7923837 HHEX G/A 63.4 90.3 57.7 36.9 50.6 62.5 100 62.3†
rs11037909 EXT2 T/C 72.9 84.5 54.6 55.1 22.2 70 84.2 72.9†
rs3740878 EXT2 T/C 72.8 89.3 55.1 55.1 22.6 69.8 92.4 72.8†
rs1113132 EXT2 C/G 73.1 90.0 44.7 44.9 77.4 70 92.5 73.3†
rs13266634 SLC30A8 C/T 71.0 89.3 76.8 64.3 79.3 75.0 94.2 69.9†
rs7480010 LOC387761 G/A 28.5 83.1 25.1 24.8 22.6 24.6 100 30.1†
rs10811661 CDKN2A/B T/C 84.8 93.9 87.0 67.2 91.5 79.2 100 83‡
rs1470579 IGF2BP2 C/A 32.6 73.1 30.7 31.9 24.1 29.2 86.7 30‡
rs7754840 CDKAL1 C/G 32.7 56.8 32.5 39.8 30.5 30.8 66.7 31‡
Data are percent. *Putative risk allele listed ﬁrst. †French, 3. ‡Scandinavian, 7. CEU, European ancestry. YRI, African ancestry.
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the metformin arm (P  0.02) and possibly the troglitazone
arm (P  0.06) (Supplementary Table 5). Adjustments for
self-reported ethnicity abolished all signiﬁcant differences
in insulin secretion by genotype at LOC387761 rs7480010.
Also, the only nominally signiﬁcant differences at
IGF2BP2 rs1470579 occurred in the lifestyle arm: higher
adjusted ISI values were seen in high-risk genotype sub-
jects compared with low-risk genotype subjects (P 
0.02), with a corresponding compensatory change in insu-
lin secretion (P  0.03) (Table 4). The analysis was
repeated by adjusting quantitative glycemic traits for BMI,
and no signiﬁcant associations were identiﬁed.
A nominally signiﬁcant interaction between genotype
and treatment arm on insulin secretion was seen at
CDKN2A/B rs10811661 in crude (P  0.03), ethnicity-
adjusted (P  0.04), and BMI-adjusted (P  0.04) analyses.
In ethnicity-adjusted analyses, we noted a nominal differ-
ential improvement in -cell function for carriers of the
protective genotype at CDKN2A/B after 1 year of troglita-
zone treatment (P  0.01) and lifestyle modiﬁcation (P 
0.05). These results persisted when adjusted for BMI alone
in both the troglitazone (P  0.03) and lifestyle modiﬁca-
tion (P  0.02) arms.
We detected one nominally signiﬁcant interaction be-
tween genotype at HHEX rs79238327 and treatment arm
on insulin sensitivity at 1 year in the crude analysis (P 
0.006). Treatment with metformin and troglitazone im-
proved the insulin sensitivity of carriers of the high-risk
genotype at HHEX rs79238327 to a greater extent than in
those who carried the low-risk genotype, an effect that was
not seen in the lifestyle arm (Supplementary Table 5).
There were no signiﬁcant interactions between genotype
and treatment arm on insulin sensitivity after adjustments
for ethnicity.
DISCUSSION
We were unable to validate the individual association of
previously reported genetic variants identiﬁed by GWAS
with diabetes incidence in the DPP; however, when taken
as an aggregate, we identiﬁed a nominally signiﬁcant
increase in diabetes incidence for those with a risk allele
score of 7.5–9 compared with those with a score of 3.5
(P  0.04). Given the higher prior probability of these
diabetes-associated variants, this nominal P value is of
interest even in the context of multiple hypotheses testing
and illustrates a potential strategy for combining a full
complement of diabetes-associated variants in risk predic-
tion as additional loci are identiﬁed.
The DPP is a unique cohort that differs from the
case-control design used in the prior GWAS studies de-
tailed above. Participants in the DPP were at relatively
high-risk at baseline (as evidenced by the 11% per year
development of diabetes in the placebo group) and were
presumably at a relatively late stage in the pathogenesis of
disease. The DPP population is very homogeneous in their
risk of type 2 diabetes: thus, as there is a smaller pheno-
typic difference between DPP participants who develop
diabetes and those who do not (compared with the case-
control designs of the published GWAS), the role of
genetic variation is more difﬁcult to ascertain. This limita-
tion is supported by the apparently higher frequency of the
risk alleles in the DPP white cohort compared with the
reference groups from the HapMap CEU population and
original GWAS cohorts.
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2506 DIABETES, VOL. 57, SEPTEMBER 2008The DPP is also limited in its ability to replicate the
GWAS ﬁndings given its interventional design, in which a
majority of participants received either a medication or
lifestyle modiﬁcation designed to prevent diabetes, again
reducing the number of incident cases and thus our ability
to observe the effect of genetic variation at multiple
diabetes-related genes. In addition, the DPP cohort is
multiethnic, introducing divergent allele frequencies and
additional population differences that may increase popu-
lation heterogeneity. The impact of these newly identiﬁed
variants is quite modest, and our power calculations show
that the cohort examined here only has marginal power to
detect such effect sizes. Furthermore, positive gene-treat-
ment interactions may have reduced our power even
further. Nevertheless, in previous work, we have been able
to convincingly replicate the association of relatively
powerful genetic factors such as TCF7L2 with diabetes,
illustrating that the DPP is an appropriate cohort to study
genetic variants of high enough frequency and/or with
strong effects (16). The SNPs examined here were marker
SNPs chosen from prior GWASs and are not known to
represent causal mutations. Further ﬁne mapping of these
gene regions will be required in larger, better-powered
studies to identify potential causal variants, because the
current study is underpowered for such an analysis. Fi-
nally, the analysis of two of the genetic loci investigated,
EXT2 and LOC387761, was largely exploratory because
these loci have not been reproducibly associated with type
2 diabetes and associated traits in more recent studies.
Interestingly, in unadjusted analyses of variants at both
LOC387761 and IGF2BP2, carriers of the presumed high-
risk genotypes had paradoxically higher insulin secretion
levels at baseline and 1 year. The LOC387761 ﬁnding is
consistent with results recently reported by Palmer et al.
(15) in the IRAS-FS, in which Hispanic Americans with the
risk variant at LOC387761 had apparently higher acute
insulin response (P  0.005) and disposition index (P 
0.04) than low-risk genotype carriers (these results were
not replicated in the African American cohort). When we
adjusted for ethnicity, however, the associations of geno-
type at LOC387761 with insulin secretion were abolished,
as were most of the IGF2BP2 associations (see below).
The disparate results of our crude and adjusted analysis
underscores the critical role ethnicity may play in con-
founding genetic association studies, particularly in ad-
mixed populations. Genetic loci with allele frequencies
that diverge signiﬁcantly across populations are particu-
larly susceptible to confounding by ethnicity when tested
for association with phenotypes whose prevalence also
differs across populations. In such a scenario, a particular
variant may simply be a marker for ancestry rather than
truly associated with the trait under study. In the DPP,
although diabetes incidence did not differ signiﬁcantly
across the ﬁve ethnic groups (19), baseline quantitative
glycemic traits did (26). LOC387761 rs7480010 and
IGF2BP2 rs1470579 SNPs have dramatically different al-
lele frequencies in white and black populations (Table 1),
which may allow genotype-phenotype associations to be
confounded by genotype-ethnicity associations. Further
studies, powered for stratiﬁed analyses of minority popu-
lations and adjusted for possible population substructure
with the use of ancestry informative markers, will be
required for investigators to fully understand the role
genetic variants at these two loci play in individual ethnic
groups. With regard to LOC387761, given the failure of
other groups to replicate the association of this locus with
type 2 diabetes (3,6,8,9) and the disappearance of statisti-
cal signiﬁcance in our results once ethnicity is taken into
consideration, the role of this locus in disease pathogene-
sis remains unclear.
We identiﬁed signiﬁcant differences in insulin secretion
by genotype at HHEX at baseline and 1-year follow-up;
however, adjusting the results for BMI abolished the effect,
emphasizing the role BMI plays in modulating the impact
of this genetic variant. Other investigators have also
identiﬁed differences in insulin secretion by genotype at
HHEX, including 1) Pascoe et al. (12), who found a
signiﬁcant decrease in 30-min insulin response in subjects
TABLE 3
Baseline quantitative traits adjusted for ethnicity
SNP Gene region Alleles* Trait High-risk genotype Heterozygote Low-risk genotype P value
rs79238327 HHEX G/A ISI 0.155 (0.149–0.162) 0.163 (0.156–0.169) 0.160 (0.151–0.169) 0.11
InsIndex 1.22 (1.16–1.28) 1.25 (1.19–1.31) 1.28 (1.19–1.36) 0.39
rs1111875 HHEX C/T ISI 0.156 (0.149–0.162) 0.163 (0.157–0.170) 0.158 (0.150–0.167) 0.08
InsIndex 1.20 (1.14–1.26) 1.24 (1.19–1.30) 1.33 (1.24–1.41) 0.01
rs1113132 EXT2 C/G ISI 0.165 (0.156–0.175) 0.158 (0.152–0.164) 0.159 (0.152–0.165) 0.27
InsIndex 1.18 (1.10–1.26) 1.24 (1.18–1.30) 1.28 (1.22–1.34) 0.07
rs11037909 EXT2 T/C ISI 0.160 (0.153–0.167) 0.162 (0.155–0.169) 0.153 (0.144–0.163) 0.26
InsIndex 1.23 (1.17–1.30) 1.23 (1.17–1.30) 1.29 (1.20–1.39) 0.47
rs3740878 EXT2 T/C ISI 0.159 (0.153–0.166) 0.163 (0.156–0.170) 0.153 (0.144–0.163) 0.19
InsIndex 1.22 (1.16–1.28) 1.23 (1.17–1.29) 1.32 (1.23–1.42) 0.14
rs13266634 SLC30A8 C/T ISI 0.162 (0.157–0.168) 0.156 (0.149–0.162) 0.154 (0.143–0.167) 0.09
InsIndex 1.22 (1.16–1.27) 1.27 (1.21–1.33) 1.32 (1.20–1.44) 0.09
rs7480010 LOC387761 G/A ISI 0.164 (0.155–0.174) 0.158 (0.151–0.164) 0.159 (0.152–0.165) 0.47
InsIndex 1.26 (1.20–1.32) 1.23 (1.16–1.29) 1.24 (1.15–1.33) 0.55
rs10811661 CDKN2A/B T/C ISI 0.161 (0.155–0.167) 0.157 (0.149–0.164) 0.143 (0.126–0.161) 0.09
InsIndex 1.24 (1.19–1.29) 1.25 (1.18–1.32) 1.28 (1.10–1.47) 0.91
rs1470579 IGF2BP2 C/A ISI 0.159 (0.151–0.168) 0.163 (0.156–0.169) 0.157 (0.151–0.163) 0.26
InsIndex 1.23 (1.15–1.31) 1.22 (1.16–1.28) 1.27 (1.21–1.33) 0.33
rs7754840 CDKAL1 C/G ISI 0.165 (0.156–0.175) 0.158 (0.152–0.164) 0.159 (0.152–0.165) 0.27
InsIndex 1.18 (1.10–1.26) 1.24 (1.18–1.30) 1.28 (1.22–1.34) 0.07
Data are least squares means (95% CI). *Risk allele listed ﬁrst. ISI is expressed as 	(
U/ml)  (mmol/l)
1; Ins Index, insulinogenic index
expressed as 	(
U/ml)/(mg/dl).
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Follow-up quantitative traits adjusted for ethnicity
Placebo Lifestyle Metformin Troglitazone
Least squares
mean (95% CI)
P
value
Least squares
mean (95% CI)
P
value
Least squares
mean (95% CI)
P
value
Least squares
mean (95% CI)
P
value
rs79238327,
HHEX ISI GG 0.154 (0.143–0.165) 0.68 0.202 (0.188–0.218) 0.18 0.194 (0.181–0.208) 0.10 0.212 (0.169–0.266) 0.02
AG 0.157 (0.147–0.167) 0.210 (0.196–0.225) 0.190 (0.177–0.204) 0.182 (0.144–0.230)
AA 0.150 (0.137–0.165) 0.226 (0.203–0.251) 0.173 (0.158–0.191) 0.171 (0.130–0.223)
Ins Index GG 1.19 (1.07–1.31) 0.45 1.15 (1.04–1.27) 0.32 1.13 (1.03–1.24) 0.90 1.09 (0.94–1.24) 0.76
AG 1.26 (1.15–1.38) 1.19 (1.08–1.30) 1.11 (1.01–1.22) 1.12 (0.97–1.28)
AA 1.26 (1.10–1.43) 1.06 (0.90–1.22) 1.13 (0.99–1.28) 1.03 (0.81–1.26)
rs1111875,
HHEX ISI CC 0.155 (0.145–0.166) 0.79 0.206 (0.191–0.221) 0.69 0.195 (0.182–0.209) 0.19 0.206 (0.164–0.259) 0.07
CT 0.153 (0.144–0.163) 0.212 (0.198–0.227) 0.187 (0.175–0.200) 0.196 (0.156–0.248)
TT 0.158 (0.144–0.172) 0.214 (0.193–0.236) 0.179 (0.164–0.196) 0.167 (0.129–0.217)
Ins Index CC 1.18 (1.06–1.30) 0.31 1.14 (1.02–1.25) 0.32 1.15 (1.04–1.26) 0.26 1.08 (0.93–1.24) 0.96
CT 1.28 (1.17–1.39) 1.19 (1.09–1.30) 1.15 (1.05–1.26) 1.08 (0.94–1.23)
TT 1.23 (1.08–1.39) 1.08 (0.93–1.23) 1.03 (0.90–1.17) 1.11 (0.91–1.33)
rs11037909,
EXT2 ISI TT 0.150 (0.140–0.161) 0.46 0.213 (0.198–0.230) 0.58 0.190 (0.178–0.204) 0.05 0.185 (0.146–0.234) 0.33
CT 0.157 (0.147–0.168) 0.205 (0.191–0.220) 0.195 (0.182–0.209) 0.188 (0.147–0.239)
CC 0.157 (0.142–0.172) 0.213 (0.191–0.238) 0.169 (0.152–0.188) 0.220 (0.167–0.289)
Ins Index TT 1.25 (1.13–1.37) 0.74 1.09 (0.98–1.20) 0.18 1.13 (1.03–1.24) 0.86 1.07 (0.93–1.21) 0.31
CT 1.21 (1.09–1.33) 1.20 (1.09–1.31) 1.11 (1.00–1.21) 1.05 (0.90–1.20)
CC 1.26 (1.10–1.43) 1.18 (1.01–1.35) 1.14 (0.98–1.31) 1.29 (1.00–1.60)
rs1113132,
EXT2 ISI CC 0.159 (0.145–0.175) 0.18 0.219 (0.198–0.242) 0.57 0.194 (0.176–0.214) 0.51 0.209 (0.163–0.267) 0.31
CG 0.149 (0.140–0.159) 0.207 (0.194–0.222) 0.190 (0.178–0.203) 0.184 (0.146–0.232)
GG 0.158 (0.148–0.169) 0.211 (0.196–0.227) 0.184 (0.172–0.197) 0.196 (0.154–0.248)
Ins Index CC 1.29 (1.13–1.46) 0.70 1.05 (0.90–1.21) 0.11 1.09 (0.95–1.24) 0.67 1.15 (0.94–1.38) 0.77
CG 1.22 (1.11–1.33) 1.13 (1.03–1.23) 1.11 (1.01–1.21) 1.07 (0.93–1.21)
GG 1.23 (1.11–1.35) 1.22 (1.11–1.34) 1.15 (1.04–1.25) 1.08 (0.92–1.23)
rs3740878,
EXT2 ISI TT 0.151 (0.141–0.162) 0.44 0.214 (0.199–0.230) 0.54 0.190 (0.177–0.203) 0.15 0.184 (0.145–0.233) 0.32
CT 0.158 (0.148–0.169) 0.205 (0.190–0.220) 0.194 (0.181–0.208) 0.189 (0.148–0.240)
CC 0.154 (0.140–0.170) 0.211 (0.189–0.237) 0.172 (0.154–0.192) 0.220 (0.167–0.289)
Ins Index TT 1.27 (1.15–1.40) 0.65 1.09 (0.98–1.20) 0.17 1.15 (1.05–1.26) 0.30 1.09 (0.96–1.23) 0.21
CT 1.22 (1.10–1.34) 1.20 (1.08–1.31) 1.08 (0.97–1.18) 1.02 (0.87–1.17)
CC 1.20 (1.04–1.37) 1.20 (1.03–1.38) 1.17 (1.00–1.34) 1.29 (1.00–1.60)
rs13266634,
SLC30A8
ISI CC 0.155 (0.146–0.164) 0.54 0.206 (0.193–0.220) 0.45 0.188 (0.176–0.200) 0.91 0.208 (0.165–0.262) 0.19
CT 0.152 (0.142–0.163) 0.214 (0.199–0.230) 0.189 (0.176–0.203) 0.186 (0.147–0.234)
TT 0.165 (0.143–0.190) 0.222 (0.194–0.255) 0.184 (0.160–0.212) 0.185 (0.136–0.250)
Ins Index CC 1.26 (1.16–1.36) 0.36 1.11 (1.01–1.21) 0.22 1.10 (1.01–1.20) 0.16 1.09 (0.96–1.22) 0.90
CT 1.21 (1.10–1.34) 1.21 (1.10–1.33) 1.13 (1.02–1.24) 1.07 (0.91–1.23)
TT 1.09 (0.85–1.34) 1.11 (0.91–1.32) 1.30 (1.09–1.53) 1.14 (0.85–1.46)
rs7480010,
LOC387761
ISI GG 0.157 (0.142–0.173) 0.59 0.204 (0.183–0.227) 0.83 0.176 (0.161–0.194) 0.21 0.188 (0.144–0.246) 0.89
GA 0.157 (0.147–0.168) 0.211 (0.195–0.227) 0.193 (0.179–0.207) 0.197 (0.155–0.250)
AA 0.152 (0.142–0.162) 0.212 (0.198–0.227) 0.190 (0.177–0.204) 0.197 (0.156–0.248)
Ins Index GG 1.34 (1.17–1.52) 0.26 1.17 (1.00–1.34) 0.98 1.15 (1.01–1.30) 0.89 1.11 (0.89–1.34) 0.79
GA 1.24 (1.12–1.37) 1.15 (1.03–1.27) 1.12 (1.01–1.23) 1.05 (0.90–1.21)
AA 1.18 (1.07–1.30) 1.15 (1.05–1.26) 1.11 (1.01–1.22) 1.10 (0.95–1.26)
rs10811661,
CDKN2A/B
ISI TT 0.154 (0.146–0.163) 0.68 0.207 (0.195–0.220) 0.13 0.190 (0.179–0.202) 0.15 0.197 (0.156–0.247) 0.96
CT 0.152 (0.140–0.165) 0.215 (0.198–0.234) 0.189 (0.174–0.205) 0.193 (0.152–0.245)
CC 0.167 (0.135–0.205) 0.257 (0.206–0.320) 0.153 (0.123–0.190) 0.199 (0.134–0.294)
Ins Index TT 1.23 (1.13–1.33) 0.46 1.18 (1.09–1.28) 0.05 1.46 (1.12–1.83) 0.12 1.01 (0.88–1.13) 0.01
CT 1.29 (1.14–1.43) 1.04 (0.92–1.17) 1.09 (0.97–1.21) 1.12 (0.94–1.31)
CC 1.06 (0.72–1.44) 1.30 (0.96–1.67) 1.12 (1.02–1.21) 1.71 (1.24–2.22)
Continued on following page
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2508 DIABETES, VOL. 57, SEPTEMBER 2008with the HHEX risk variant; 2) Grarup et al. (13), who
found that the risk variant of HHEX was associated with a
decreased acute insulin response after OGTT or tolbut-
amide challenge; and 3) Staiger et al. (14), who showed
that the risk variant of HHEX was associated with de-
creased insulin secretion after OGTT or intravenous glu-
cose challenge.
We did not replicate the associations of several other
diabetes-related variants with insulin secretion docu-
mented by others (6,12–15). We may have been underpow-
ered to replicate these previous ﬁndings because of a
smaller effect of these genes on insulin secretion and
sensitivity when compared with those identiﬁed by the
original GWAS investigations. An alternative explanation
is that in these participants at high risk for diabetes,
pathological changes had already taken place that ob-
scured the effect of single genetic variants on these
physiological parameters.
We identiﬁed a single genomic region with a possible
genotype-intervention interaction. The previously re-
ported impairment in -cell function in carriers of the
high-risk genotype at CDKN2A/B rs10811661 when com-
pared with the alternative genotypes was augmented by
treatments that improved insulin sensitivity: subjects with
the low-risk genotype at CDKN2A/B improved -cell func-
tion to a greater extent than those with the high-risk
genotype after treatment with troglitazone and possibly
lifestyle modiﬁcation for 1 year, suggesting that they may
have beneﬁted more from these interventions. This inter-
action was identiﬁed in both crude and ethnically adjusted
analysis. More scientiﬁc investigation on the biological
consequences of genotypic variation at CDKN2A/B will be
required to determine why subjects with the high-risk
genotype, who had decreased insulin secretion, beneﬁted
less from metformin or lifestyle modiﬁcation than low-risk
genotype subjects. Although this is one of the ﬁrst reports
of a potential pharmacogenetic interaction with one of the
newly identiﬁed type 2 diabetes gene regions, this ﬁnding
is limited by the modest nominal P values obtained here,
the multiple tests performed, and the unclear mechanism
of action. Independent conﬁrmation of these complex
gene-environment interactions is needed.
In summary, although we were unable to replicate the
ﬁndings of the original GWAS scans in our smaller, predi-
abetic population, our quantitative trait analysis conﬁrms
differences in insulin secretion by genotype at HHEX and
CDKN2A/B. This study also emphasizes the important role
ancestry may play at the diabetes-associated SNPs in
LOC387761 and IGF2BP2, which have dramatically differ-
ent allele frequencies in populations of European and
African ancestry. Finally, we have identiﬁed a potential
genotype-intervention interaction at CDKN2A/B; however,
this hypothesis-generating ﬁnding needs to be conﬁrmed
by additional studies. Further studies are required to
better understand the differences in insulin dynamics that
result from variants at these and the other diabetes-
associated genes identiﬁed to date.
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Placebo Lifestyle Metformin Troglitazone
Least squares
mean (95% CI)
P
value
Least squares
mean (95% CI)
P
value
Least squares
mean (95% CI)
P
value
Least squares
mean (95% CI)
P
value
rs1470579,
IGF2BP2
ISI CC 0.161 (0.147–0.177) 0.52 0.225 (0.204–0.247) 0.02 0.198 (0.181–0.216) 0.32 0.191 (0.147–0.248) 0.31
AC 0.152 (0.142–0.163) 0.217 (0.202–0.234) 0.187 (0.175–0.200) 0.185 (0.146–0.234)
AA 0.154 (0.144–0.164) 0.197 (0.184–0.212) 0.184 (0.172–0.198) 0.205 (0.162–0.258)
Ins Index CC 1.17 (1.01–1.34) 0.55 1.07 (0.93–1.21) 0.03 1.12 (1.02–1.23) 0.84 1.20 (1.00–1.42) 0.17
AC 1.26 (1.15–1.39) 1.10 (0.99–1.21) 1.11 (1.01–1.21) 0.99 (0.84–1.14)
AA 1.23 (1.12–1.35) 1.25 (1.14–1.37) 1.15 (1.02–1.29) 1.09 (0.93–1.25)
rs7754840,
CDKAL1
ISI CC 0.159 (0.145–0.175) 0.18 0.219 (0.198–0.242) 0.57 0.194 (0.176–0.214) 0.51 0.209 (0.163–0.267) 0.31
CG 0.149 (0.140–0.159) 0.207 (0.194–0.222) 0.190 (0.178–0.203) 0.184 (0.146–0.232)
GG 0.158 (0.148–0.169) 0.211 (0.196–0.227) 0.184 (0.172–0.197) 0.196 (0.154–0.248)
Ins Index CC 1.29 (1.13–1.46) 0.70 1.05 (0.90–1.21) 0.11 1.09 (0.95–1.24) 0.67 1.15 (0.94–1.38) 0.77
CG 1.22 (1.11–1.33) 1.13 (1.03–1.23) 1.11 (1.01–1.21) 1.07 (0.93–1.21)
GG 1.23 (1.11–1.35) 1.22 (1.11–1.34) 1.15 (1.04–1.25) 1.08 (0.92–1.23)
Data are least squares means (95% CI) and are also adjusted for the baseline values. Risk allele listed ﬁrst. ISI is expressed as 	(
U/ml) 
(mmol/l)
1; Ins Index, insulinogenic index expressed as 	(
U/ml)/(mg/dl).
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